The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Deciding Between Hormone Therapies in Patients With ER+/PR+ Tumors

Ragene Rivera, MD
Published Online:2:15 PM, Tue August 12, 2014
Ragene Rivera, MD, medical oncologist, Texas Oncology-El Paso Cancer Treatment Center, discusses how she decides between hormone therapies in patients with ER+/PR+ tumors.

This segment is a part of our Case-Based Peer Perspectives. View the case details > >
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.